GlassScriptPhysician profile
Layne Fielder
NPI 1740472380
$5,359.04
in general payments reported to CMS, 2019-2025
24 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $715 · 2021: $450 · 2022: $583 · 2023: $270 · 2024: $1,306 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.41 |
| Education | $379.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.81 | 2019-2025 | |
| Janssen Biotech, INC. | $692.41 | 2022-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $643.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $507.85 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $397.81 | 2019-2025 | |
| Lilly USA, LLC | $377.24 | 2019-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $339.35 | 2019-2025 | Nemluvio |
| Ucb, INC. | $259.38 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $228.33 | 2019-2025 | |
| Leo Pharma INC. | $188.38 | 2019-2022 | |
| Pfizer INC. | $184.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $137.73 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $85.04 | 2019 | |
| Amgen INC. | $67.54 | 2020-2021 | |
| Revance Therapeutics, INC. | $63.76 | 2024 | Daxxify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $49.60 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.54 | 2020-2023 | Arazlo |
| Incyte Corporation | $41.68 | 2022-2024 | Opzelura |
| Dermira, INC. | $33.41 | 2019-2020 | |
| Allergan, INC. | $29.23 | 2020 | |
| Mayne Pharma Commercial LLC | $23.03 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.91 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2023 | Spevigo |
| Epi Health, LLC | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Fielder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.